SBRA Stock Analysis: Sabra Healthcare REIT | NASDAQ
REIT - Healthcare Facilities | NASDAQ, USA | Market Cap: 5.014m USD | 12M Return: 18.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 62.4M
Qual. Beats: 0
Rev. Trend: 96.3%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sabra Health Care REIT, Inc. (NASDAQ: SBRA) is a self-administered, self-managed real estate investment trust that owns and invests in healthcare-related real estate across the United States and Canada. The company is headquartered in Tustin, California, was incorporated on May 10, 2010, and trades as a mid-cap stock within the Real Estate sector under the GICS Health Care REITs sub-industry.
As a healthcare-focused REIT, Sabra primarily generates revenue by leasing its properties to operators of skilled nursing facilities, senior housing, and other healthcare assets, typically through long-term triple-net lease agreements. REITs are generally required to distribute a substantial portion of their taxable income to shareholders in the form of dividends, making them a common income-oriented investment vehicle.
- Skilled nursing occupancy recovery drives rent coverage
- Interest rate cuts ease borrowing costs and support dividend
- Senior housing portfolio expansion through HOLZ joint venture
| Net Income: 156.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.10 > 1.0 |
| NWC/Revenue: -26.26% < 20% (prev 6.00%; Δ -32.26% < -1%) |
| CFO/TA 0.07 > 3% & CFO 366.7m > Net Income 156.2m |
| Net Debt (2.59b) to EBITDA (466.5m): 5.55 < 3 |
| Current Ratio: 0.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (256.0m) vs 12m ago 6.52% < -2% |
| Gross Margin: 63.48% > 18% (prev 67.64%; Δ -4.15% > 0.5%) |
| Asset Turnover: 15.02% > 50% (prev 13.76%; Δ 1.26% > 0%) |
| Interest Coverage Ratio: 2.33 > 6 (EBIT TTM 269.9m / Interest Expense TTM 115.9m) |
| A: -0.04 (Total Current Assets 123.5m - Total Current Liabilities 336.9m) / Total Assets 5.59b |
| B: -0.37 (Retained Earnings -2.05b / Total Assets 5.59b) |
| C: 0.05 (EBIT TTM 269.9m / Avg Total Assets 5.41b) |
| D: 0.99 (Book Value of Equity 2.79b / Total Liabilities 2.80b) |
| Altman-Z'' = -0.07 = B |
As of July 18, 2026, the stock is trading at USD 20.11 with a total of 3,427,504 shares traded. Over the past week, the price has changed by +2.50%, over one month by +11.41%, over three months by -1.36% and over the past year by +18.32%.
Current recommended Stop Loss: 18.90 (which is 6% or 2.6 ATR below the current price).
Sabra Healthcare REIT has received a consensus analysts rating of 3.85. Therefore, it is recommended to buy SBRA.
- StrongBuy: 5
- Buy: 1
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 22.1 | 9.7% |
P/E Trailing = 31.5556
P/E Forward = 32.1543
P/S = 6.1466
P/B = 1.8127
P/EG = 5.2841
Revenue TTM = 812.8m USD
EBIT TTM = 269.9m USD
EBITDA TTM = 466.5m USD
Long Term Debt = 2.31b USD (from longTermDebt, last quarter)
Short Term Debt = 8.92m USD (from shortTermDebt, last quarter)
Debt = 2.71b USD (from shortLongTermDebtTotal, last quarter) + Leases 20.2m
Net Debt = 2.59b USD (calculated: Debt 2.71b - CCE 123.5m)
Enterprise Value = 7.60b USD (5.01b + Debt 2.71b - CCE 123.5m)
Interest Coverage Ratio = 2.33 (Ebit TTM 269.9m / Interest Expense TTM 115.9m)
EV/FCF = 20.73x (Enterprise Value 7.60b / FCF TTM 366.7m)
FCF Yield = 4.82% (FCF TTM 366.7m / Enterprise Value 7.60b)
FCF Margin = 45.11% (FCF TTM 366.7m / Revenue TTM 812.8m)
Net Margin = 19.21% (Net Income TTM 156.2m / Revenue TTM 812.8m)
Gross Margin = 63.48% ((Revenue TTM 812.8m - Cost of Revenue TTM 296.8m) / Revenue TTM)
Gross Margin QoQ = 61.38% (prev 62.05%)
Tobins Q-Ratio = 1.36 (Enterprise Value 7.60b / Total Assets 5.59b)
Interest Expense / Debt = 4.27% (Interest Expense 115.9m / Debt 2.71b)
Taxrate = 1.25% (1.95m / 156.1m)
NOPAT = 266.5m (EBIT 269.9m * (1 - 1.25%))
Current Ratio = 0.37 (Total Current Assets 123.5m / Total Current Liabilities 336.9m)
Debt / Equity = 0.97 (Debt 2.71b / totalStockholderEquity, last quarter 2.79b)
Debt / EBITDA = 5.55 (Net Debt 2.59b / EBITDA 466.5m)
Debt / FCF = 7.06 (Net Debt 2.59b / FCF TTM 366.7m)
Total Stockholder Equity = 2.79b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.89% (Net Income 156.2m / Total Assets 5.59b)
RoE = 5.61% (Net Income TTM 156.2m / Total Stockholder Equity 2.79b)
RoCE = 5.30% (EBIT 269.9m / Capital Employed (Equity 2.79b + L.T.Debt 2.31b))
RoIC = 4.80% (NOPAT 266.5m / Invested Capital 5.55b)
WACC = 4.84% (E(5.01b)/V(7.73b) * Re(5.17%) + D(2.71b)/V(7.73b) * Rd(4.27%) * (1-Tc(0.01)))
Discount Rate = 5.17% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.64 | Cagr: 4.23%
[DCF] Terminal Value 76.49% ; FCFF base≈355.2m ; Y1≈381.8m ; Y5≈463.2m
[DCF] Fair Price = 17.91 (EV 7.11b - Net Debt 2.59b = Equity 4.52b / Shares 252.2m; r=8.35% [WACC [floored]]; 5y FCF grow 8.49% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 96.32 | Revenue CAGR: 13.64% | SUE: 0.74 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.17 | Chg30d=-4.74% | Revisions=-25% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.17 | Chg30d=-5.56% | Revisions=-40% | Analysts=3
EPS current Year (2026-12-31): EPS=0.67 | Chg30d=-3.60% | Revisions=-25% | GrowthEPS=+11.0% | GrowthRev=+14.7%
EPS next Year (2027-12-31): EPS=0.74 | Chg30d=-5.31% | Revisions=+0% | GrowthEPS=+10.9% | GrowthRev=+10.7%
[Analyst] Revisions Ratio: -44% (up=1, down=5)